Firsito

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Firsito

What is Firsito?

Firsito is a pharmaceutical medication specifically formulated to address conditions related to hormonal regulation and reproductive health. It contains the active ingredient ganirelix acetate, which belongs to a class of medications known as gonadotropin-releasing hormone (GnRH) antagonists.

Primary Mechanism and Use

The medication is primarily utilized in the context of assisted reproductive technology (ART). Its main function is to prevent premature surges of luteinizing hormone (LH). By controlling the timing of this hormone, Firsito helps ensure that eggs within the ovaries have sufficient time to mature properly before ovulation occurs.

How it Functions

Firsito works by blocking the action of GnRH on the pituitary gland. Under normal physiological conditions, GnRH signals the release of LH. In controlled ovarian stimulation cycles, an early rise in LH can cause the ovaries to release eggs too soon, which may interfere with fertility treatments. Firsito provides a rapid and reversible suppression of this hormonal signal, allowing healthcare providers to better manage the timing of the reproductive cycle.

Characterization

As a GnRH antagonist, Firsito is characterized by its immediate onset of action. Unlike other types of hormonal suppressors that may require a longer period to achieve downregulation, Firsito begins inhibiting the secretion of LH shortly after administration. This characteristic allows for a shorter overall duration of treatment during a fertility cycle.

What side effects are possible with Firsito?

Firsito: Possible Side Effects and Safety Information

Adverse reactions associated with Firsito (Escitalopram) are categorized by frequency and the body system affected, as documented in official government regulatory information.

Frequency-Classified Adverse Reactions

The most commonly reported adverse effects are categorized as Very Common (affecting 1 in 10 people or more) and include headache and nausea. Effects classified as Common (affecting 1 in 100 to 1 in 10 people) typically involve the Nervous System (e.g., insomnia, somnolence, dizziness, fatigue) and the Gastrointestinal System (e.g., dry mouth, constipation, diarrhea). Disturbances in sexual function, such as decreased libido and ejaculation disorder, are also documented as common.

Serious Adverse Reactions and Safety Constraints

The official safety profile notes several serious, though rare, adverse events. These include Serotonin Syndrome, a potentially life-threatening condition, and hyponatremia (low sodium levels), which can occur particularly within the first few weeks of starting treatment. Other serious cardiac concerns include QT interval prolongation and associated risk of heart rhythm changes.

Safety data emphasizes an increased risk of suicidal thoughts and behavior in adolescents, children, and young adults (under 25), especially during the initial months of therapy or following dose adjustments. Due to potential risk, Firsito is contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs). Specific safety considerations are noted for older adults, who may have an increased risk of hyponatremia, and for patients with hepatic impairment.

Overdose and Emergency Response

Overdose and when to seek help

A suspected overdose of Firsito (Escitalopram) requires immediate medical attention. This emergency is defined by documented effects on the central nervous system (CNS) and the cardiovascular system, as outlined in official regulatory prescribing information.


Documented Manifestations and Severe Risks

Overdose may present with various clinical manifestations. These include CNS effects such as convulsions, coma, dizziness, somnolence (drowsiness), and insomnia. Cardiovascular signs include sinus tachycardia (rapid heart rate), hypotension (low blood pressure), and ECG changes. Serious risks highlighted in regulatory documentation include QT prolongation and the rare occurrence of Torsade de pointes. Furthermore, there is a documented risk of developing Serotonin Syndrome in the overdose setting.


Emergency Actions and Treatment

Due to the potential for severe outcomes, individuals must contact emergency services or a poison control center immediately. Treatment is strictly symptomatic and supportive, and continuous cardiac monitoring is required until the patient is stable. Regulatory labeling explicitly states that there is no specific antidote for Escitalopram overdose. Procedures like dialysis are considered unlikely to be beneficial, reinforcing the focus on managing symptoms and maintaining vital functions.

Therapeutic Uses of Firsito

Firsito: Main Uses and Benefits

The primary purpose of Firsito is applied across domains where additional symptomatic support is needed in mental health contexts marked by significant emotional distress, cognitive disturbance, and symptoms that interfere with daily functioning. It is commonly used to manage groups of symptoms that may become intense or disruptive, assisting with functional stability during difficult episodes.

Firsito is relevant for conditions characterized by periods of heightened symptoms and emotional tension, including Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Panic Disorder, Social Anxiety Disorder (SAD), and Obsessive-Compulsive Disorder (OCD).

“The medication is commonly used to help ease the overall burden of symptoms that create noticeable functional strain.”

The treatment helps to ease the overall burden of persistent sadness, supports the capacity for enjoyment, and is used for managing excessive worry. By moderating the intensity of these manifestations, Firsito contributes to improved comfort during periods of heightened symptoms and supports the patient during difficult episodes by easing distress.


Quick Fact: Relief for Obsessional and Anxiety Symptoms

Firsito is applied in clinical settings that involve acute or unstable symptom patterns, such as recurrent panic attacks or intrusive thoughts, to provide supportive relief when symptoms interfere with routine activities.

Eligibility and Restrictions for Use

Eligibility and Contraindications

Firsito's official eligibility is determined by regulatory agencies based on age, concurrent medications, and underlying health conditions.

Populations Who Must Not Use Firsito (Contraindicated)

  • Patients with known hypersensitivity to escitalopram, citalopram, or any excipients.
  • Individuals currently taking Monoamine Oxidase Inhibitors (MAOIs), including irreversible MAOIs, linezolid, or intravenous methylene blue.
  • Patients with known QT-interval prolongation or congenital long QT syndrome, or those using other QT-prolonging medicines (like pimozide).

Age-Related Eligibility

Population Regulatory Status
Adults (18+ years) Approved for use.
Adolescents (12-17 years) Approved for Major Depressive Disorder (US-FDA).
Children (Under 7 years) Use not established for any indication.
Elderly (ge 65 years) Use permitted, but lower dosage is typically recommended.

Conditional Use

Use requires caution or a lower maximum dosage in patients with hepatic impairment (liver dysfunction) or severe renal impairment (kidney dysfunction). Caution is also advised for those with a history of seizures or mania/hypomania and during pregnancy and lactation, where use is generally not recommended unless the potential benefit justifies the risk.

What should I know about interactions with other medicines?

Firsito Interactions with Other Medicines and Products

The interaction profile of Firsito (Escitalopram) is defined by its effects as a Selective Serotonin Reuptake Inhibitor (SSRI), which dictates several constraints and mandatory precautions in co-administration with other substances.

Formal Prohibitions and Restrictions

Firsito is formally contraindicated for co-administration with Monoamine Oxidase Inhibitors (MAOIs), including irreversible types, due to the high risk of Serotonin Syndrome. A mandatory 14-day separation period is required when switching between Firsito and an MAOI. The co-administration of Pimozide and medicinal products known to prolong the QT interval are also prohibited.

Documented Pharmacodynamic and Pharmacokinetic Interactions

Interaction Type Interacting Substances/Class Official Outcome
Pharmacodynamic Risk Other Serotonergic Agents (e.g., Triptans, Tramadol, St. John's Wort) Increased risk of Serotonin Syndrome.
Hemostasis Risk Drugs interfering with hemostasis (e.g., NSAIDs, Warfarin) Increased risk of abnormal bleeding.
Pharmacokinetic Alteration CYP Inhibitors (e.g., Cimetidine) Documented increase in Firsito plasma concentration (AUC and Cmax).

Firsito may be taken with or without food. However, use with alcohol is advised against due to the potential for additive central nervous system effects. Regulatory documents also note that caution is required in patients with conditions causing altered metabolism, as this may influence the severity of interactions.

Mechanism of Action

Selective Serotonin Reuptake Inhibition

The core mechanism of Firsito is the highly targeted inhibition of the Sodium-dependent Serotonin Transporter (SERT) (SLC6A4), the protein responsible for clearing the neurotransmitter serotonin (5-HT) from the synaptic cleft. The active molecule, Escitalopram, binds to the SERT, blocking reuptake and causing an acute increase in the concentration of available serotonin outside the nerve cell. This primary molecular action initiates the potentiation of serotonergic signaling in the Central Nervous System (CNS).


Time-Dependent Neural Adaptation

The functional process is reliant on a slower neural adaptation that follows the initial blockade. The sustained increase in serotonin drives the gradual desensitization of 5-HT1A autoreceptors—presynaptic feedback regulators that normally limit 5-HT release. Over time, this adaptive change overrides the negative feedback loop, allowing for sustained, consistent potentiation of serotonergic activity and modulating neural circuit function.


Chronic Systemic Modulation

Chronic modulation of serotonin signaling influences fundamental CNS pathways. This sustained action is linked to the modulation of neurotrophic factors (such as BDNF), influencing the functional plasticity of key central neural networks.

Dosage and Administration Information

How to Use Firsito

Firsito (Escitalopram) is administered exclusively via the oral route, typically taken as a single daily dose either in the morning or the evening. This medication is available in two authorized dosage forms: film-coated tablets in strengths of 5 mg, 10 mg (scored), and 20 mg (scored), and an oral solution. The official instructions permit the medicine to be taken with or without food, providing flexibility for daily scheduling. If using the oral solution, it may be accurately measured and then mixed with water, orange juice, or apple juice prior to intake.

The regulatory dosing protocol establishes a starting and typical maintenance dose of 10 mg once daily for most adult patients. The maximum authorized dose is 20 mg once daily. Any adjustment from the initial 10 mg dose should occur only after a minimum treatment interval of one week. Specific populations require adherence to a lower maximum dose; for both older adults (over 65 years) and individuals with hepatic (liver) impairment, the official maximum daily dose is restricted to 10 mg. Consistent with long-term protocols, Firsito is intended for maintenance use, and the regulatory procedure requires that treatment cessation must always be managed by a gradual reduction in dose (tapering) rather than abrupt discontinuation.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section summarizes the key findings from clinical research and trials involving the drug, focusing on what was evaluated rather than what the drug does.


Research Evidence in Condition A

Research has explored whether the drug, a targeted synthetic disease-modifying antirheumatic drug (tsDMARD), has an impact on disease activity in adults with Condition A.

  • The drug is a targeted synthetic disease-modifying antirheumatic drug (tsDMARD) that acts on specific intracellular signaling pathways.
  • Studies evaluated clinical outcomes in adults with moderate-to-severe active Condition A who have had an inadequate response to one or more TNF-blockers.
  • RCTs included findings of interest for the drug across various populations with Condition A. Studies investigated the change in pain and joint stiffness, and also measured markers of inflammation.
  • The evidence from multiple studies is available for its use in this patient population.

Efficacy and Combination Studies

Multiple studies have examined the drug's efficacy as a monotherapy and in combination with non-biological DMARDs (nbDMARDs) in adult patients with active disease.

  • Studies examined the potential for reduction of disease activity over time, as measured by standard clinical indices.
  • Combination therapy has been studied in comparison to monotherapy. Research has reported on the timing of observed changes in disease markers in these studies.

Safety Profile

The safety profile of the drug has been evaluated in multiple Phase 3 clinical trials. Reported side effects were categorized in research.

  • Common adverse events observed in the research included respiratory tract infections, headache, and nasopharyngitis.
  • The treatment's safety profile was evaluated in study populations, with common adverse events reported. The long-term safety profile was a focus of ongoing extension studies.

Key Studies & References

  1. Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (contRAst 1)
  2. Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system

Frequently Asked Questions (FAQ)

Common questions about Firsito (FAQ)

Q: What is the main reason Firsito is prescribed?

According to official regulatory documents, Firsito (escitalopram) is indicated for the acute and maintenance support of adults and adolescents experiencing Major Depressive Disorder (MDD). It is also prescribed for the acute management of Generalized Anxiety Disorder (GAD) in adults. This classification defines its core use as a selective serotonin reuptake inhibitor (SSRI).


Q: Is Firsito considered a treatment for long-term conditions?

Official information indicates that Firsito is prescribed for the maintenance treatment of Major Depressive Disorder, suggesting continued use may be necessary to support emotional balance. Its application for Generalized Anxiety Disorder also aligns with the typical treatment protocols for chronic conditions.


Q: How quickly does Firsito usually start to show its expected effects?

Regulatory information indicates the drug’s mechanism begins acting soon after intake, although the observable functional effects take longer to develop. Official sources suggest it may take several weeks before the full, expected benefit of the medication is typically felt.


Q: Is Firsito the same type of medicine as [similar drug]? What's the difference?

Firsito is categorized as a Selective Serotonin Reuptake Inhibitor (SSRI). It is distinguished by its structure as the purified S-enantiomer (a single isomer) of the drug citalopram. This single-isomer composition is described as supporting a selective action on the serotonin system, distinguishing its structure from racemic compounds.


Q: Does Firsito have a generic version available?

The active ingredient in Firsito is escitalopram. The availability of multiple products containing escitalopram from various manufacturers confirms the regulatory existence of generic equivalents for the drug.


Q: Are there any widely known interactions between Firsito and common vitamins or supplements?

Official guidance advises caution against combining Firsito with the herbal supplement St. John's Wort, due to the increased risk of certain side effects. Regulatory documents do not provide enough specific data to confirm the safety of combining Firsito with other common non-herbal vitamins or supplements.


Q: Can Firsito be taken with pain relievers like ibuprofen or acetaminophen?

Official product information notes that co-administering Firsito with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen, may potentially increase the risk of abnormal bleeding. Acetaminophen (paracetamol), which is not an NSAID, is not specifically listed in regulatory documents as having this particular interaction risk.


Q: What is the typical duration of time Firsito stays in the system?

Official pharmacological summaries indicate that Firsito has a typical half-life of 27–33 hours. The half-life refers to the amount of time it takes for the body to eliminate half of the drug from the system. This characteristic supports its standard classification as a once-daily medicine.


Q: Are there any foods or drinks that should be avoided when using Firsito?

Regulatory information states that Firsito can be taken with or without food, offering flexibility in daily use. However, use with alcohol is advised against because it may potentially increase the likelihood of central nervous system side effects like dizziness and drowsiness.


Q: Does Firsito cause weight gain or weight loss in studies?

Regulatory documents list changes in appetite or weight as documented side effects of Firsito. Clinical studies indicate that changes in weight are reported, but official information notes that individual results may vary.


Q: What does 'contraindicated' mean in the context of Firsito?

When a medicine is contraindicated, it means that official product information specifies a particular condition, medication, or circumstance under which Firsito must not be used. This is because the risk of serious harm or adverse effects in that situation is deemed too high to justify use.


Q: Is Firsito associated with any long-term safety concerns described in official documents?

Regulatory documents note a range of potential side effects, including rare, serious events such as Serotonin Syndrome, low sodium levels (hyponatremia), and certain heart rhythm concerns (QT interval prolongation). An increased risk of suicidal thoughts and behavior is noted, particularly in young adults during the first few months of therapy.


Q: Can Firsito affect blood pressure or heart rate?

The official safety profile for Firsito details serious cardiac concerns, including a documented risk of QT interval prolongation. This effect relates to the electrical activity of the heart and may be associated with heart rhythm changes.


Q: Is it possible for Firsito to interact with over-the-counter cold and flu medicines?

Firsito carries interaction warnings for drug classes often found in cold and flu medicines. These include substances that affect blood clotting, such as NSAIDs, and other serotonergic agents that can increase the risk of Serotonin Syndrome. It is advised to check the active ingredients of any over-the-counter preparations.


Q: How is Firsito's intended action described compared to a placebo in clinical trials?

Regulatory documentation, particularly concerning maintenance trials, summarizes Firsito's comparison to a placebo (an inactive substance). These studies reported findings that supported the use of Firsito for the prevention of relapse, specifically showing a statistically significant longer time to relapse compared to a placebo.


Q: Can Firsito interact with herbal teas or natural remedies?

Official information specifically contraindicates the use of the herbal remedy St. John's Wort with Firsito. Generally, due to the limited regulatory data for most combinations, it is often stated that there is not enough information to confirm the safety of mixing Firsito with other herbal remedies or complementary medicines.


Q: What happens if a person stops taking Firsito suddenly?

Official guidance indicates that treatment cessation is typically managed by a gradual reduction in dose (tapering) to help reduce the potential for adverse effects. Stopping abruptly may lead to a discontinuation syndrome that includes symptoms such as nausea, dizziness, headaches, irritability, and a prickling sensation on the skin.


Q: Does taking Firsito require any specific lifestyle changes?

Official safety constraints advise using caution when performing activities that require mental alertness, such as driving or operating hazardous machinery. Furthermore, use with alcohol is advised against because of the risk of additive central nervous system effects like drowsiness.


Q: Are there specific symptoms that should prompt a person to seek immediate medical help while on Firsito?

The patient information leaflet lists serious symptoms that require immediate attention. These include signs of Serotonin Syndrome (e.g., fast heart rate, fever, severe muscle stiffness), severe allergic reactions (e.g., difficulty breathing, swelling of the face), and certain symptoms of Angle-Closure Glaucoma (e.g., eye pain, vision changes).


Q: Is Firsito used to treat the cause of a disease or just the symptoms?

Firsito's mechanism involves inhibiting the reuptake of serotonin, which leads to an increase in the concentration of serotonin in the brain’s synapses. This action is understood as modulating the underlying chemical imbalances and neural pathways that contribute to the conditions it is used to support.


Q: Is Firsito generally well-tolerated according to official sources?

The official safety profile provides detailed frequency data. It indicates that while some side effects are very common (such as headache and nausea), and others are common (like dizziness and fatigue), the most serious side effects associated with Firsito are considered rare.


Q: Are there restrictions on driving or operating machinery while using Firsito?

Official product information advises patients to use caution when operating machinery or driving a car until they understand how Firsito affects them. This caution is advised because the medicine may interfere with certain cognitive and motor functions.


Q: Is Firsito available under different brand names internationally?

Firsito's active ingredient, escitalopram, is marketed globally under various brand names. These names differ depending on the specific country or region of sale, which is a common practice for widely used pharmaceuticals.


Q: Is Firsito a new medication, or has it been used for a long time?

Firsito's active component, escitalopram, was first approved for medical use in the United States in 2002. This date indicates that the medication has been available on the market and used in clinical practice for an extended period of time.


Q: Is there a maximum length of time Firsito is studied for continuous use?

Regulatory studies, particularly those focused on preventing relapse in Major Depressive Disorder, have established the drug's effectiveness for maintenance therapy for up to 36 weeks. This research supports the continued use of Firsito for long-term therapeutic goals.


Q: Are there specific instructions for what to do if a dose of Firsito is missed?

The protocol for a missed dose is described as taking the dose as soon as it is remembered. However, if the time is closer to the next scheduled dose, the missed dose is typically skipped, and guidance advises against taking a double dose to compensate.


Q: What does the research say about the long-term effectiveness of Firsito?

Long-term clinical trials have been conducted to demonstrate Firsito's sustained benefit. These maintenance studies confirm the drug's long-term effectiveness in preventing relapse, showing a statistically significant longer time to relapse compared to a placebo.


Q: Is Firsito a controlled substance?

In the United States, Firsito (escitalopram) is classified as a prescription-only (Rx-only) medicine, meaning it requires a licensed healthcare professional’s authorization. It is not currently scheduled or classified as a controlled substance by the Drug Enforcement Administration (DEA).


Q: Does Firsito interact with common antacids?

Official information indicates a potential for interaction between Firsito and certain antacids, specifically those containing the H2 blocker famotidine. This combination may elevate the risk of an irregular heart rhythm. Always confirm all medicines being used with a pharmacist.

How should Firsito be stored and disposed of?

How to Store and Dispose of Firsito?

Firsito requires storage at Controlled Room Temperature (CRT), specifically between 20 C and 25 C (68 F and 77 F), as documented in regulatory labeling. The medicine must be kept away from excess heat and is explicitly directed to not be frozen.

Storage Protection

The product must be protected from moisture and direct light. It must be kept in its original container and the cap must remain tightly closed to maintain stability. For safety, Firsito must be stored out of the sight and reach of children.

Disposal Requirements

Official instructions prohibit discarding unused or expired Firsito via wastewater or household waste. Disposal must be performed in accordance with local requirements for pharmaceutical waste, and patients should consult their pharmacist for advice on proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Firsito found in:

A-Z Index: